Clinical Trials Logo

Psoriasis clinical trials

View clinical trials related to Psoriasis.

Filter by:

NCT ID: NCT05855967 Active, not recruiting - Psoriatic Arthritis Clinical Trials

A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India

Start date: June 27, 2023
Phase: Phase 4
Study type: Interventional

The main purpose of this study is to investigate the safety and tolerability of ixekizumab in participants in India with moderate-to-severe plaque psoriasis (PsO) or active psoriatic arthritis (PsA)

NCT ID: NCT05730725 Active, not recruiting - Psoriasis Clinical Trials

A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis

Start date: April 3, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate clinical effectiveness and safety of BMS-986322 in participants with moderate-to-severe psoriasis.

NCT ID: NCT05645627 Active, not recruiting - Psoriasis Clinical Trials

A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis

Start date: February 10, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of participants with moderate to severe plaque-type psoriasis.

NCT ID: NCT05604898 Active, not recruiting - Psoriasis Clinical Trials

A Phase 2 Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With Moderate-to-Severe Plaque Psoriasis

Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of the study drug recombinant anti-IL-17A humanized monoclonal antibody in Chinese participants with moderate-to-severe plaque psoriasis.

NCT ID: NCT05478499 Active, not recruiting - Psoriasis Clinical Trials

Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp Psoriasis

Start date: October 6, 2022
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of deucravacitinib to placebo in participants with moderate-to-severe scalp psoriasis.

NCT ID: NCT05427175 Active, not recruiting - Psoriasis Clinical Trials

Evaluation of the Effect of Narrowband UVB Versus Methotrexate on Serum Chitotriosidase Level in Psoriasis

Start date: January 10, 2022
Phase: Phase 4
Study type: Interventional

The aim of the study is to evaluate the effect of NB-UVB versus MTX on serum Chitotriosidase level in psoriatic patients.

NCT ID: NCT05401006 Active, not recruiting - Psoriasis Clinical Trials

Effect of Acitretin Versus Narrowband Ultraviolet B on Neopterin Level in Psoriatic Patients .

Start date: June 5, 2021
Phase: Phase 4
Study type: Interventional

To evaluate effect of acitretin versus Narrowband UVB on serum level of neopterin in psoriatic patients.

NCT ID: NCT05388916 Active, not recruiting - Clinical trials for Moderate to Severe Chronic Plaque Psoriasis

A Real-world Study to Assess Safety and Effectiveness of Secukinumab in Pediatric Plaque Psoriasis Patients in China

Start date: September 8, 2022
Phase:
Study type: Observational

This is a non-interventional, prospective, multi-center real world setting study, aiming to provide safety and effectiveness data in Chinese pediatric patients with moderate to severe plaque psoriasis treated with Cosentyx® for up to 52 weeks.

NCT ID: NCT05377944 Active, not recruiting - Plaque Psoriasis Clinical Trials

Assessment on Efficacy and Safety of BAT2306 and Cosentyx® in Plaque Psoriasis Patients

Start date: October 26, 2022
Phase: Phase 3
Study type: Interventional

This study is a multicenter, randomized, double-blind, parallel-arm, Phase 3 study designed to compare efficacy, safety, immunogenicity, and PK of BAT2306 with Cosentyx in patients with moderate to severe plaque psoriasis. The study is composed of a ≤ 28-day screening period, a 24-week initial treatment period (Treatment Period 1 [TP1]), and a 28-week secondary treatment period (Treatment Period 2 [TP2]). The study will be a maximum of 56 weeks.

NCT ID: NCT05366855 Active, not recruiting - Clinical trials for Generalized Pustular Psoriasis

Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasis

GEMINI2
Start date: April 21, 2022
Phase: Phase 3
Study type: Interventional

This is a Phase 3, long term extension study to evaluate the safety and efficacy of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).